Senate Drug Safety Hearings Will Take Broad View Of FDA Process
This article was originally published in The Pink Sheet Daily
Executive Summary
The Senate Health Committee is planning a series of hearings on drug safety issues in March on topics including FDA’s drug approval process and the delayed “Critical Path” drug development initiative. It is premature to predict how drug safety controversies will impact FDA post-marketing authority, House and Senate staffers say.
You may also be interested in...
Allergenic Product Reclassification Will Be Discussed At April 7 Advisory Committee
The committee will assess whether Class IIIA products should remain licensed or be pulled from the market. An update on FDA's "critical path" drug development initiative is also on the agenda.
Allergenic Product Reclassification Will Be Discussed At April 7 Advisory Committee
The committee will assess whether Class IIIA products should remain licensed or be pulled from the market. An update on FDA's "critical path" drug development initiative is also on the agenda.
FDA Drug Safety Oversight Board Will Include VA, Other Agencies
The panel is the primary feature of FDA's proposal to reform drug safety review within the agency; other features include the creation of a drug safety website. The panel and website are intended to increase drug safety "oversight" and "openness" at FDA.